ライフサイエンスコーパス: pleural effusion

1 tellite nodules, lymph node enlargement, and pleural effusion).

2 PEL, which arises in a hypoxic environment (pleural effusions).

3 stimulation after excluding one patient with pleural effusion.

4 ostoperative AF or postoperative pericardial/pleural effusion.

5 nts were postoperative AF and pericardial or pleural effusion.

6 esis is performed to identify the cause of a pleural effusion.

7 s. 19+/-6 bpm, p<0.01) than those with lower pleural effusion.

8 ations, and one patient with chronic chylous pleural effusion.

9 tein, release of inflammatory cytokines, and pleural effusion.

10 tion, air bronchogram, nodular opacities and pleural effusion.

11 peutic strategy for the control of malignant pleural effusion.

12 ctasis or pneumonia on chest radiograph, and pleural effusion.

13 e II (n = 88) studies for the development of pleural effusion.

14 schedule may result in a higher incidence of pleural effusion.

15 patient irritability, small pericardial +/- pleural effusion.

16 o be secondary to a decrease or absence of a pleural effusion.

17 ed pleural thickening coupled with a massive pleural effusion.

18 3 thrombocytopenia, grade 4 neutropenia, and pleural effusion.

19 rs); 12% required intensive care and 26% had pleural effusion.

20 ashimoto thyroiditis and pneumonia with left pleural effusion.

21 ar-interstitial syndrome, consolidation, and pleural effusion.

22 ractory MPP children or in MPP children with pleural effusion.

23 anulomas as well as ascites and a left-sided pleural effusion.

24 nical characters, such as refractoriness and pleural effusion.

25 t upper lobe mass along with a moderate-size pleural effusion.

26 owed mild pulmonary edema with a small right pleural effusion.

27 rentially diagnose tuberculous and malignant pleural effusion.

28 aphy showed an enlarged heart with bilateral pleural effusion.

29 ntional T2-weighted sequences revealed small pleural effusions.

30 airment were more likely to have significant pleural effusions.

31 cy and the presence, size, and laterality of pleural effusions.

32 e may reduce the incidence of pneumonia with pleural effusions.

33 ed as factors associated with development of pleural effusions.

34 s Fontan morbidity, particularly duration of pleural effusions.

35 ain the prominent and persistent hemorrhagic pleural effusions.

36 ne, it induced transient production of large pleural effusions.

37 ty, thickened bronchial walls, and bilateral pleural effusions.

38 loped low cardiac output, and 3 patients had pleural effusions.

39 rodesis was successful in treating malignant pleural effusions.

40 evaluated; (c) unsuspected pneumonia; or (d) pleural effusions.

41 iation of chylous and nonchylous ascites and pleural effusions.

42 lator-associated pneumonia, atelectasis, and pleural effusions.

43 xudative pleural effusions from transudative pleural effusions.

44 atients presented with worsening dyspnea and pleural effusions.

45 PCs (13.2% vs 40.5%, P < 0.001), symptomatic pleural effusion (11.6% vs 26.4%, P = 0.003), pleural ef

46 -up data were available for 31 of 39 treated pleural effusions: 11 (35%) had CR, 18 (58%) had PR, and

47 ), thoracic duct dilatation (4% vs 0, P=.3), pleural effusion (12% vs 6%, P=.2), or ascites (10% vs 6

48 (20%), intrathoracic lymphadenopathy (16%), pleural effusion (12%), reticular infiltration (4%), and

49 ophic scar formation (35), atelectasis (12), pleural effusion (13), recurrent sternal depression (5),

50 %), oral ulcers (24.2%), joint pain (23.0%), pleural effusion (16.5%) and increase in abdominal girth

51 rapy was most effective in the resolution of pleural effusions (2 of 2), ascites (6 of 8), and hydrop

52 64 [32%] of 200, respectively; P < .001) and pleural effusions (47 [23.5%] of 200 vs 16 [8%] of 200,

53 rainage and/or abdominal collections (9.3%), pleural effusion (8.3%), postoperative bleeding (5.6%),

54 opathy (23%), mass-like consolidation (17%), pleural effusion (8.6%), and honey combing (5.7%).

55 ping on the rare disseminated tumor cells in pleural effusions across a panel of 32 lung adenocarcino

56 Significant pleural effusions after the Fontan operation prolong hos

57 Pleural effusion agreement also differed between pulmona

58 tients in the once-daily group experienced a pleural effusion (all grades, 20% vs 39% P < .001).

59 ily resulted in significantly lower rates of pleural effusion (all grades, 7% v 16%; P = .024) and gr

60 ome features was strong (eg, alpha = .78 for pleural effusion and ascites) but was lower for others (

61 ded the use of ultrasonography for ruling-in pleural effusion and assisting its drainage, ascites dra

62 ersistent fever caused by pneumonia (n = 2), pleural effusion and atelectasis (n = 1), or liver absce

63 st cancer cells isolated from the metastatic pleural effusion and atypical ductal hyperplasia mammary

64 adiologically as interstitial pneumonia with pleural effusion and clinically as hypoxemic respiratory

65 CAP with pleural effusion and documented pneumococcal CAP were di

66 th dasatinib compared with imatinib, whereas pleural effusion and grade 3/4 thrombocytopenia were mor

67 ion in lung injury, as assessed by volume of pleural effusion and histological analyses (significant

68 When pleural effusion and intra-abdominal hypertension were s

69 Among patients with malignant pleural effusion and no previous pleurodesis, there was

70 unrelated to alectinib: acute renal failure; pleural effusion and pericardial effusion; and brain met

71 (one due to pulmonary oedema and one due to pleural effusion and pneumonitis).

72 r talc slurry in the management of recurrent pleural effusion and pneumothorax.

73 urs in mouse models of malignant lung cancer pleural effusion and spontaneous colon cancer metastasis

74 lations of leukocytes and malignant cells in pleural effusions and accurately predict disease state i

75 In both groups, pleural effusions and air bronchograms are common, and K

76 Two patients, including one with large pleural effusions and another with ventricular tachycard

77 n of peritoneal spread, presence and size of pleural effusions and ascites, lymphadenopathy, and dist

78 renchyma, which is sometimes associated with pleural effusions and diffuse alveolar hemorrhage.

79 nt has altered the traditional management of pleural effusions and empyema in children, resulting in

80 tered to improve the drainage of complicated pleural effusions and empyemas and it is the most effect

81 Prominent serosanguinous pleural effusions and hemorrhagic mediastinitis were fou

82 hy of the chest demonstrated large bilateral pleural effusions and hemorrhagic mediastinitis.

83 ared to be related to significant, prolonged pleural effusions and longer hospitalizations.

84 transfusions, and the presence of bilateral pleural effusions and multi-lobar atelectasis/consolidat

85 gnificantly post antibiotic treatment in the pleural effusions and pleural macrophages up-regulated m

86 by progression of respiratory insufficiency, pleural effusions and pulmonary edema, and, ultimately,

87 s observed, in the other one, pneumonia with pleural effusion, and as a consequence of inflammatory i

88 primary tumor, pleural metastases, malignant pleural effusion, and ascites obtained during disease pr

89 arch for thickening of the gallbladder wall, pleural effusion, and ascites.

90 ata suggest a strong impact of PCV13 on CAP, pleural effusion, and documented pneumococcal pneumonia,

91 cul-de-sac, peritoneal implants, ipsilateral pleural effusion, and intratumoral hemorrhage.

92 Reported events included seizure, pleural effusion, and lymphocytopenia.

93 pic support, thoracostomy tube drainage of a pleural effusion, and prolonged antimicrobial therapy.

94 ts and included disease progression, anemia, pleural effusion, and thrombocytopenia.

95 required no further treatment), two cases of pleural effusion, and two cases of moderate pain (one ca

96 on with tamponade associated with pneumonia, pleural effusion, and urinary tract infection.

97 y, and most animals also developed leukemia, pleural effusion, and, in some cases, ascites associated

98 monstrated mediastinal widening, adenopathy, pleural effusions, and air-space disease.

99 norexia, and nausea), skin rash, cytopenias, pleural effusions, and fatigue.

100 samples (tumor and normal pleura), malignant pleural effusions, and in established mesothelioma cell

101 of thiourea, W/D increased to 5.5 and marked pleural effusions appeared, but there were no difference

102 Hemorrhage and pleural effusion are prominent pathological features of

103 Over 200000 pleural effusions are attributable to cancer in the UK a

104 heir presence in urine, chylous ascites, and pleural effusions are consistent with their ability to m

105 nvolvement-thoracic duct dilatation, chylous pleural effusion, ascites, and LALM-is more common in LA

106 that increased gall bladder wall thickness, pleural effusion, ascites, hepatomegaly, and splenomegal

107 ngs included enlarged abdominal lymph nodes, pleural effusions, ascites, and dilatation of the thorac

108 tial Lobar Collapse, Targeted Physiotherapy, Pleural Effusion assessment, and PEEP optimisation.

109 estigated the risk factors and management of pleural effusion associated with dasatinib therapy for c

110 sion may be instrumental to the treatment of pleural effusion-associated lung restriction and cyclica

111 was designed to determine the prevalence of pleural effusion at approximately 28 days after cardiac

112 le-blind trial involving patients with large pleural effusions at two academic medical centres in, Na

113 pulmonary infection, aspiration pneumonitis, pleural effusion, atelectasis, cardiopulmonary edema, an

114 ion, but 1 patient developed pericardial and pleural effusion attributed to pericardial instrumentati

115 The presence of a pleural effusion before dasatanib therapy predicted the

116 liphatic analogues toward MCF-7 cells (human pleural effusion breast adenocarcinoma cell line).

117 Lung congestion and pericardial and pleural effusions can cause attenuation in the ECG poten

118 rom 41.3% to 29.7% (P < .001), the number of pleural effusion cases decreased by 53% (167 to 79; P <

119 Malignant pleural effusion causes disabling dyspnea in patients wi

120 RNA from pleural effusion cells was examined to determine TGF-bet

121 ntestinal and/or pulmonary lymphangiectasia, pleural effusions, chylothoraces and/or pericardial effu

122 Chylous pleural effusion (chylothorax) frequently accompanies ly

123 Those with CNS disease, pleural effusion, circulating lymphoma cells > or = 5,00

124 -2.2% to 17.6%) or postoperative pericardial/pleural effusion (colchicine, 103 patients [57.2%]; plac

125 phosphorylation in MT cells, derived from a pleural effusion, compared with cells from the primary t

126 adiograph revealed hilar adenopathy and left pleural effusion; computed tomography scan showed a 2-cm

127 s predictive of CT outcome, although lack of pleural effusion correlated with clinical stability.

128 investigated whether fibulin-3 in plasma and pleural effusions could meet sensitivity and specificity

129 In cytology-negative suspected malignant pleural effusions, CT-guided pleural biopsy is a better

130 Among patients with malignant pleural effusion, daily drainage of pleural fluid via an

131 Pericardial and pleural effusions developed in one patient after cycles

132 ever, higher morbidity of tachypnea/dyspnea, pleural effusion, diarrhea, hepatosplenomegaly, consciou

133 )CD16(-) NK cells isolated from inflammatory pleural effusions display a potent regulatory activity.

134 to improve overall survival in patients with pleural effusion due to malignant pleural mesothelioma,

135 tasis have a history of asbestos exposure or pleural effusion due to various causes.

136 With no cure for malignant pleural effusion, efforts are focused on symptomatic man

137 ion defect(s), and (g) perfusion defect from pleural effusion equal to one third or more of the pleur

138 a (seven [5%]), cholangitis (five [3%]), and pleural effusion (five [3%]).

139 2S protein were observed in seven of 17 lung pleural effusion fluids of lung cancer patients.

140 es vascular permeability and is important in pleural effusion formation.

141 s immunosuppressive therapy, who had a large pleural effusion, found on a chest radiograph during the

142 nd primary cultures, as well as in a primary pleural effusion from a breast cancer patient.

143 d we also detected CXCL12-gamma in malignant pleural effusions from patients with breast cancer.

144 values can help in differentiating exudative pleural effusions from transudative pleural effusions.

145 such as severe leakage, fluid accumulation, pleural effusion, gall-bladder wall thickening and rapid

146 -172 mL vs. 80+/-87 mL, p<0.0001, for higher pleural effusion group vs. lower pleural effusion group)

147 /-124 mL vs. 23+/-29 mL, p<0.0001 for higher pleural effusion group vs. lower pleural effusion group,

148 for higher pleural effusion group vs. lower pleural effusion group) was greater than the estimated l

149 for higher pleural effusion group vs. lower pleural effusion group, respectively).

150 n in local pulmonary infiltrates group or in pleural effusion group.

151 Patients were divided into higher and lower pleural effusion groups according to the median value (2

152 s following induction of an antigen-specific pleural effusion, guinea pigs were injected intrapleural

153 RATIONALE: Patients with malignant pleural effusions have significant dyspnea and shortened

154 DLT in later courses included pleural effusions, hemangiomatosis, and GI hemorrhage.

155 ommonly seen pulmonary complications include pleural effusion, hemothorax, atelectasis, pulmonary ede

156 n 480 (39.5%) patients including symptomatic pleural effusion in 366 (30.1%) patients, respiratory in

157 63 patients, CT demonstrated an increase in pleural effusion in 46 (73%), periaortic changes in 21 (

158 d JIMT-1 breast cancer cells, derived from a pleural effusion in a patient who displayed clinical res

159 Pleural effusion in acute lung injury or acute respirato

160 To assess the effects of pleural effusion in patients with acute lung injury on l

161 ions in 13 group A versus 4 group B fetuses, pleural effusions in 2 group A versus 0 group B, ascites

162 Readers 1 and 2 found pleural effusions in 40 and 41 stage III and 20 and 21 s

163 Small-bore catheter drainage of persistent pleural effusions in lung transplant recipients is usual

164 The prevalence of pleural effusions in the patients undergoing only CABG s

165 -expiratory pressure 10 benefit in reversing pleural effusion-induced de-recruitment.

166 Unilateral pleural effusion instillation (13 mL/kg), intra-abdomina

167 s a primary target organ with serosanguinous pleural effusions, intra-alveolar edema, and hemorrhagic

168 al hypertension (15 mm Hg), and simultaneous pleural effusion/intra abdominal hypertension.

169 analysis revealed that histology, malignant pleural effusion, intraparenchymal liver metastasis, and

170 Pleural effusion is a frequent finding in patients with

171 Treatment of symptomatic carcinomatous pleural effusions is primarily directed at local palliat

172 areas of consolidation, areas of cavitation, pleural effusions, linear opacities, septal thickening,

173 Proliferative responses of pleural effusion lymphocytes were examined in response t

174 ned as a stable episome in latently infected pleural effusion lymphoma (PEL) cells.

175 and host-cell genomes of a latently infected pleural effusion lymphoma cell line BCBL1.

176 In pleural effusion lymphoma cell lines that express variab

177 s constitutively expressed in HHV-8-positive pleural effusion lymphoma cell lines.

178 rantly accumulated in latently KSHV-infected pleural effusion lymphoma cells and results in increased

179 transcription in the latently infected BCBL1 pleural effusion lymphoma-derived cell line.

180 svirus 8 (HHV-8) causes Kaposi's sarcoma and pleural effusion lymphoma.

181 ecreased intracellular bacterial survival in pleural-effusion macrophages of the guinea pigs infected

182 Large pleural effusions may develop in a small proportion of p

183 The lymphoma presented with pleural effusions, mediastinal and cervical adenopathy,

184 Malignant pleural effusion (MPE) confers dismal prognosis and has

185 Malignant pleural effusion (MPE) is challenging to manage.

186 Malignant pleural effusion (MPE) is the lethal consequence of vari

187 Malignant pleural effusion (MPE) poses a significant clinical prob

188 us pleural effusion (TPE, n = 50), malignant pleural effusion (MPE, n = 41), other cases including pn

189 quantified MCs in human and murine malignant pleural effusions (MPEs) and evaluated the fate and func

190 revealed a globular dilated heart, bilateral pleural effusions, myocyte apoptosis, and transmural myo

191 areas of hazy increased attenuation (n = 1), pleural effusion (n = 1), and areas of cavitation (n = 1

192 e included patients with pneumonia (n = 28), pleural effusion (n = 13), pleural empyema (n = 4), lung

193 l thickening (n = 7), consolidation (n = 5), pleural effusion (n = 4), and solitary endobronchial les

194 Complications included pleural effusion (n = 7), pneumothorax (n = 2), pericard

195 ction (n=1 [2%]), skin infection (n=1 [2%]), pleural effusion (n=1 [2%]), pericardial infusion (n=1 [

196 Adverse events included procedure-related pleural effusion (n=2), cholecystitis (n=1), and additio

197 For treatment of malignant pleural effusion, nonsteroidal anti-inflammatory drugs (

198 drainage changed the management of malignant pleural effusion, not solely by offering an alternative

199 In conclusion, the prevalence of pleural effusions occupying more than 25% of the hemitho

200 Pleural effusions occur during dasatinib therapy, partic

201 Pleural effusion occurred in 27% of patients (grade 3 to

202 Pleural effusion occurred in 48 patients (35%; grade 3/4

203 One case of thrombosis and one case of pleural effusion occurred.

204 mouse xenograft (Sparky-X) from a malignant pleural effusion of a 12-year-old Persian male with auto

205 a population established in culture from the pleural effusion of a breast cancer patient showed disti

206 cancer cell lines in vitro, or isolated from pleural effusions of mesothelioma patients triggered dow

207 els of activity were seen with exosomes from pleural effusions of mesothelioma patients.

208 Cells isolated from ascites or pleural effusions of patients with metastatic breast can

209 ictor of anthrax was mediastinal widening or pleural effusion on a chest radiograph.

210 re (HR, 2.55; 95% CI, 1.15 to 5.63; P=0.02), pleural effusion on chest radiograph (HR, 2.56; 95% CI,

211 lking status, and ascites, moderate-to-large pleural effusion on CT images was significantly associat

212 reasing periaortic hematoma, and hemorrhagic pleural effusion on imaging identify patients with compl

213 , central lung involvement, crazy paving and pleural effusion on initial CT chest have potential prog

214 Moderate-to-large pleural effusion on preoperative CT images in patients w

215 hematocrit <30% (OR, 2.0; 95% CI, 1.3-3.2), pleural effusion on presenting chest x-ray (OR, 1.6; 95%

216 L/One hundred and twenty eight patients with pleural effusions on thoracic CT who underwent thoracent

217 hospital admissions for bronchitis (one) and pleural effusion (one), grade 3 increase in aminotransfe

218 Methods Patients with NSCLC (stage IIIB with pleural effusion or stage IV according to American Joint

219 Patients with stage IIIB NSCLC with pleural effusion or stage IV NSCLC, who had Eastern Coop

220 l of patients with advanced (stage IIIB with pleural effusion or stage IV) non-small-cell lung cancer

221 Patients with stage IIIB (with pleural effusion or supraclavicular nodes) to IV NSCLC a

222 Radiographs were assessed for presence of pleural effusions or lymphadenopathy.

223 uce a pleurodesis in patients with recurrent pleural effusions or pneumothorax should be investigated

224 he greatest odds of readmission, followed by pleural effusion [OR 7.52 (95% CI, 6.01-9.41)], pneumoth

225 chemotherapy-naive patients with stage IIIB (pleural effusion) or IV NSCLC, without restrictions by h

226 chemotherapy-naive patients with stage IIIB (pleural effusion) or stage IV NSCLC of any histology or

227 Nodular opacities, reticular opacities, pleural effusion, or lymphadenopathy were not observed i

228 Patients with stage IIIB disease with pleural effusion, or stage IV NSCLC and Eastern Cooperat

229 ned or recurrent pain (P<0.0001), increasing pleural effusion (P=0.0003), and both the maximum diamet

230 that regulate the pathogenesis of malignant pleural effusion (PE) associated with advanced stage of

231 milar effect, achieving control of malignant pleural effusion (pleurodesis).

232 riables studied were the occurrence of PPCs, pleural effusion, pneumonia, and pulmonary embolism.

233 of nine (33.3%) major complications, such as pleural effusion, pneumothoraces or perihepatic hemorrha

234 , pulmonary congestion, respiratory failure, pleural effusion, pneumothorax, or unplanned requirement

235 s (mediastinal bleeding, pneumothoraces, and pleural effusions), postdischarge complications, reopera

236 duration of post-Fontan hospitalization and pleural effusion, postoperative plastic bronchitis, need

237 These larger pleural effusions produce dyspnea but not chest pain or

238 There were 4 independent risk factors for pleural effusion: prolonged surgery (OR = 1), surgery on

239 For dyspnea and malignant pleural effusions, providers should offer thoracentesis,

240 correlated significantly with the volume of pleural effusions (r = 0.79, p < 0.00001).

241 of confirmed or suspected mesothelioma with pleural effusion, recruited from 12 hospitals in the UK.

242 leural effusion (11.6% vs 26.4%, P = 0.003), pleural effusion requiring drainage (1.7% vs 9.9%, P = 0

243 = 49, 12%), incisional hernia (n = 22, 6%), pleural effusion requiring intervention (n = 21, 5%), ne

244 cantly (P<0.0001) associated with pneumonia, pleural effusions requiring drainage, and maximum postop

245 other signs (ie, halo sign, hypodense sign, pleural effusion, reversed halo sign) is unknown.

246 pted method for the treatment of symptomatic pleural effusions secondary to mesotheliomas.

247 HH is a transudative pleural effusion seen in 5%-10% of cirrhosis patients, i

248 none), dyspnoea (six [2%] vs one [1%]), and pleural effusion (six [2%] vs none).

249 cancer were thrombocytopenia (eight [11%]), pleural effusion (six [8%]), and increased lipase (five

250 Bedside US can be used to detect a pleural effusion so well in critically ill patients that

251 Large pleural effusions sometimes occur after coronary artery

252 Subcutaneous edema, ascites, pleural effusion, splenomegaly, varices, portal venous t

253 ociations among themselves and with ascites, pleural effusions, subcutaneous edema, and low mean seru

254 B but increased risk of rapid progression to pleural effusion TB.

255 Pleural effusions that occupied more than 25% of the hem

256 Regarding the detection of pleural effusions, there was no significant performance

257 sed included noncalcified pulmonary nodules, pleural effusion, thoracic duct dilatation, hepatic and

258 Among patients with malignant pleural effusion, thoracoscopic talc poudrage, compared

259 entify chylous versus nonchylous ascites and pleural effusions through use of multipoint Dixon fat qu

260 the selected conditions ranged from 0.22 for pleural effusion to 0.0004 for tension pneumothorax.

261 ndwelling pleural catheter was placed in the pleural effusion to drain the fluid fully.

262 We enrolled 91 cases, including tuberculous pleural effusion (TPE, n = 50), malignant pleural effusi

263 ned in 31 lung transplant recipients who had pleural effusions treated with catheter drainage were re

264 , and information on pleural fluid findings, pleural effusion treatment, and cardiac surgery was obta

265 ly pyrexia (four [3%]), and hypertension and pleural effusion (two [1%] each).

266 and in group C, neutropenia (four [6%]) and pleural effusion (two [3%]).

267 imary malignancy and a symptomatic malignant pleural effusion underwent small-bore-catheter thoracost

268 Pleural effusion volume was determined on each CT scan s

269 d causing medium lobe atelectasis; bilateral pleural effusion was also present.

270 Pleural effusion was an expected and problematic toxicit

271 Pneumococcal pneumonia with pleural effusion was associated with a limited number of

272 rsus 30%) were more prevalent with imatinib; pleural effusion was more common with dasatinib (17% ver

273 functional residual capacity by 368 mL when pleural effusion was present and by 184 mL when intra-ab

274 ents identified in either treatment arm, and pleural effusion was the only drug-related, nonhematolog

275 Pleural effusion was uncommon (2/64, 3%).

276 or absence of parenchymal abnormalities and pleural effusions was noted.

277 loss and septal thickening, with or without pleural effusion, was never seen in the absence of acute

278 us pneumoniae responsible for pneumonia with pleural effusion, we determined the capsular polysacchar

279 Patients with higher pleural effusion were older (62+/-16 yr vs. 54+/-17 yr,

280 First occurrences of pleural effusion were reported with dasatinib, with the

281 Subpleural sparing and pleural effusion were seen approximately in one-fifth an

282 Subpleural sparing and pleural effusion were seen in approximately 23% (28/120)

283 Pleural effusions were classified as exudates or transud

284 Orthotopic tumors and pleural effusions were clearly visualized at MR imaging

285 tocytologically proven symptomatic malignant pleural effusions were included in this phase I toxicity

286 The incidence of pleural effusions were not significantly different betwe

287 Pleural effusions were present in one-half of the patien

288 effusions.Methods: Patients presenting with pleural effusions were prospectively recruited to an obs

289 h cytologically negative suspected malignant pleural effusions were recruited.

290 Pleural effusions were seen in 16 (57%) patients with PE

291 Thirty three (26%) of the 128 pleural effusions were transudates and 95 (74%) were exu

292 and asthenia (40 [5%] vs 23 [3%]); grade 3-4 pleural effusions were uncommon (ten [1%] vs three [<1%]

293 er radiologic findings (multiple nodules and pleural effusion) were less frequent, but appeared later

294 nia in children is frequently complicated by pleural effusions, which rarely progress to empyema.

295 (1:1) for which 106 patients with malignant pleural effusion who had not previously undergone pleuro

296 The association of pleural effusion with other conditions mirrored that in

297 o of right to left lung mass, association of pleural effusion with other conditions, and frequency of

298 Larger doses of TGF-beta(2) induced larger pleural effusions with relatively low pleural fluid WBC

299 tomography (CT) findings for characterizing pleural effusions with the use of attenuation values.

300 ew-onset heart failure symptoms or recurrent pleural effusions within 2 years of lung transplantation